Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 10
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.15%
|
$620,000
$62.9 P/Share
|
|
Feb 09
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-75.37%
|
$930,000
$62.42 P/Share
|
|
Feb 09
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+37.5%
|
$90,000
$6.44 P/Share
|
|
Feb 09
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.29%
|
$620,000
$62.65 P/Share
|
|
Feb 08
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-85.52%
|
$930,000
$62.2 P/Share
|
|
Feb 08
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 08
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.29%
|
$610,000
$61.8 P/Share
|
|
Feb 05
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-67.17%
|
$885,000
$59.88 P/Share
|
|
Feb 05
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 04
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-77.68%
|
$885,000
$59.01 P/Share
|
|
Feb 04
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 03
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-68.85%
|
$459,610
$59.92 P/Share
|
|
Feb 03
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+47.91%
|
$46,740
$6.32 P/Share
|
|
Feb 03
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-81.12%
|
$900,000
$60.12 P/Share
|
|
Feb 03
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 02
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-52.38%
|
$459,610
$59.71 P/Share
|
|
Feb 02
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+47.91%
|
$46,740
$6.32 P/Share
|
|
Feb 02
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-74.61%
|
$885,000
$59.26 P/Share
|
|
Feb 02
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
6,770
-97.78%
|
$379,120
$56.01 P/Share
|
|
Feb 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
6,770
+34.03%
|
$40,620
$6.79 P/Share
|
|
Feb 01
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-66.84%
|
$428,450
$55.86 P/Share
|
|
Feb 01
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+47.91%
|
$46,740
$6.32 P/Share
|
|
Feb 01
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-86.48%
|
$825,000
$55.68 P/Share
|
|
Feb 01
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 29
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-76.17%
|
$840,000
$56.7 P/Share
|
|
Jan 29
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 29
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,813
-31.77%
|
$157,528
$56.69 P/Share
|
|
Jan 29
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+30.45%
|
$19,691
$7.18 P/Share
|
|
Jan 29
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-72.87%
|
$2,800,000
$56.72 P/Share
|
|
Jan 29
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 28
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-54.99%
|
$2,800,000
$56.01 P/Share
|
|
Jan 28
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 28
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-68.65%
|
$825,000
$55.87 P/Share
|
|
Jan 28
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 28
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.14%
|
$560,000
$56.53 P/Share
|
|
Jan 27
2021
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
40,000
-69.0%
|
$2,360,000
$59.16 P/Share
|
|
Jan 27
2021
|
Lance Baldo Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$280,000
$7.8 P/Share
|
|
Jan 27
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-74.28%
|
$885,000
$59.18 P/Share
|
|
Jan 27
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 27
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.11%
|
$570,000
$57.42 P/Share
|
|
Jan 26
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.14%
|
$630,000
$63.97 P/Share
|
|
Jan 26
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-86.04%
|
$975,000
$65.17 P/Share
|
|
Jan 26
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 26
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-53.18%
|
$3,200,000
$64.09 P/Share
|
|
Jan 26
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 25
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-59.18%
|
$990,000
$66.46 P/Share
|
|
Jan 25
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 25
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-53.1%
|
$3,300,000
$66.37 P/Share
|